ALYSSA CARAMAGNO: Open Payments
NPI 1902157472 · FRASER, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$788 in 30 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $125 · 2025 $788
Food & beverage: $788
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $166 |
| E.R. Squibb & Sons, L.L.C. | 4 | $164 |
| Neurocrine BioSciences, Inc. | 2 | $155 |
| ABBVIE INC. | 13 | $142 |
| Alkermes, Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Corium, LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
Products named: CAPLYTA, COBENFY, INGREZZA, VRAYLAR, LYBALVI, ABILIFY MAINTENA, AUSTEDO XR, REXULTI.
Industry payments across MI — which companies pay providers there.
